Drug Profile
Research programme: cancer therapeutics - Leuchemix
Alternative Names: LC-913 series; LC812 series; LCVJ series; LCVJ2 seriesLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Leuchemix
- Class
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 29 Sep 2008 Leuchemix receives approval to undertake clinical safety trials of LC 1